Gert Ossenkoppele, Emeritus Professor of Hematology from Amsterdam UMC, EuroBloodNet subnetwork, in Amsterdam, The Netherlands, discusses the use of intensive treatment in elderly patients with AML. The median age at diagnosis is 68 to 70+ years, with approximately 60% of new cases diagnosed in adults aged 65 years and older. The 5-year survival for all patients with AML is 28.3%, which decreases to 2.6% in adults aged 75 years and older. Prof Ossennkoppele notes that chemotherapy is less effective in elderly patients, and these patients may experience increased toxicity of chemotherapy.